share_log

Barclays Maintains Overweight on Dr Reddy's Laboratories, Lowers Price Target to $66

Benzinga Real-time News ·  Oct 25, 2022 19:04

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and lowers the price target from $69 to $66.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment